NCT05722275

Brief Summary

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Jan 2023

Longer than P75 for all trials

Geographic Reach
2 countries

13 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Jan 2023Dec 2028

First Submitted

Initial submission to the registry

December 30, 2022

Completed
2 days until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Expected
Last Updated

February 14, 2023

Status Verified

February 1, 2023

Enrollment Period

12 months

First QC Date

December 30, 2022

Last Update Submit

February 12, 2023

Conditions

Keywords

Artificial IntelligenceClassificationGastric CancerPeritoneal MetastasesComputed TomographyRadiomics

Outcome Measures

Primary Outcomes (1)

  • The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system

    AUC of the intelligent analysis system in predicting peritoneal metastasis for gastric cancer.

    three months

Secondary Outcomes (1)

  • The accuray of intelligent analysis system in predicting peritoneal metastasis

    three months

Other Outcomes (3)

  • The statistical significance of intelligent analysis system in risk stratification

    Three years

  • Progression-free survival time

    Three years

  • Overall survival

    Three years

Study Arms (13)

Peking University Cancer Hospital & Institute

Peking University Cancer Hospital \& Institute collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Zhenjiang First People's Hospital

Zhenjiang First People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

The First Affiliated Hospital of Zhengzhou University

The First Affiliated Hospital of Zhengzhou University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Nanfang Hospital of Southern Medical University

Nanfang Hospital of Southern Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Guizhou Provincial People's Hospital

Guizhou Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Henan Cancer Hospital

Henan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Yunnan Cancer Hospital

Yunnan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Guangdong Provincial People's Hospital

Guangdong Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Guangzhou Medical University

Affiliated Cancer Hospital and Institute of Guangzhou Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Fujian Medical University Union Hospital

Fujian Medical University Union Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Shanxi Province Cancer Hospital

Shanxi Province Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Sun Yat-sen University

Sun Yat-sen University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Scientific Institute San Raffaele

Scientific Institute San Raffaele collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.

Diagnostic Test: Peritoneal metastasis status ascertainment

Interventions

Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Fujian Medical University Union HospitalGuangdong Provincial People's HospitalGuangzhou Medical UniversityGuizhou Provincial People's HospitalHenan Cancer HospitalNanfang Hospital of Southern Medical UniversityPeking University Cancer Hospital & InstituteScientific Institute San RaffaeleShanxi Province Cancer HospitalSun Yat-sen UniversityThe First Affiliated Hospital of Zhengzhou UniversityYunnan Cancer HospitalZhenjiang First People's Hospital

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All included patients are initially diagnosed as peritoneal metastasis-negative by CT, but later confirmed with the actual peritoneal metastasis status in laparoscopic exploration.

You may qualify if:

  • (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
  • (2) with both enhanced CT and laparoscopy;
  • (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
  • (4) without other evidence of distant metastasis, and no stage IV features on CT.

You may not qualify if:

  • (1) previous abdominal surgery;
  • (2) previous abdominal malignancies or inflammatory diseases;
  • (3) time intervals between CT and laparoscopy longer than 2 weeks;
  • (4) CT image artifacts that undermine peritoneal lesion assessment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Peking University Cancer Hospital & Institute

Beijing, China

RECRUITING

Fujian Medical University Union Hospital

Fuzhou, China

RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, China

RECRUITING

Guangdong Provincial People's Hospital

Guangzhou, China

RECRUITING

Nanfang Hospital of Southern Medical University

Guangzhou, China

RECRUITING

Sun Yat-Sen University Cancer Hospital

Guangzhou, China

RECRUITING

Guizhou Provincial People's Hospital

Guiyang, China

RECRUITING

Yunnan Cancer Hospital

Kunming, China

RECRUITING

Shanxi Province Cancer Hospital

Taiyuan, China

RECRUITING

Henan Cancer Hospital

Zhengzhou, China

RECRUITING

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China

RECRUITING

Zhenjiang First People's Hospital

Zhenjiang, China

RECRUITING

Scientific Institute San Raffaele

Milan, Italy

RECRUITING

Related Publications (5)

  • Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. doi: 10.1093/annonc/mdw350. No abstract available.

    PMID: 27664260BACKGROUND
  • Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Feb;20(2):167-192. doi: 10.6004/jnccn.2022.0008.

    PMID: 35130500BACKGROUND
  • Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH. Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. J Surg Oncol. 2010 Dec 1;102(7):753-7. doi: 10.1002/jso.21685.

    PMID: 20812349BACKGROUND
  • Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013 Mar;68(3):251-5. doi: 10.1016/j.crad.2012.07.015. Epub 2012 Sep 14.

    PMID: 22985749BACKGROUND
  • Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, Ying XJ, Sun YS, Fu J, Wang XX, Li LM, Li ZH, Zhang DF, Zhang Y, Li ZM, Shan F, Bu ZD, Tian J, Ji JF. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019 Mar 1;30(3):431-438. doi: 10.1093/annonc/mdz001.

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Central Study Contacts

Yali Zang, Ph.D

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 30, 2022

First Posted

February 10, 2023

Study Start

January 1, 2023

Primary Completion

December 31, 2023

Study Completion (Estimated)

December 31, 2028

Last Updated

February 14, 2023

Record last verified: 2023-02

Locations